Truist raised the firm’s price target on Praxis Precision (PRAX) to $700 from $500 and keeps a Buy rating on the shares. The company’s Q4 update was “notable” for its completed NDA submissions for ulixa for Essential Tremor and relu for DEE, or developmental and epileptic encephalopathies, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision price target raised to $130 from $95 at Wedbush
- Praxis Precision price target raised to $412 from $357 at Deutsche Bank
- Praxis Precision price target raised to $433 from $275 at Baird
- Praxis Precision price target raised to $305 from $282 at Wells Fargo
- Praxis Therapeutics: Advancing Late-Stage Neurology Pipeline Toward Commercialization with Multibillion-Dollar Market Potential